Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function

Rachel A. Rigg, Joseph Aslan, Laura D. Healy, Michael Wallisch, Marisa L D Thierheimer, Cassandra P. Loren, Jiaqing Pang, Monica Hinds, Andras Gruber, Owen McCarty

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The Tec family kinase Bruton's tyrosine kinase (Btk) plays an important signaling role downstream of immunoreceptor tyrosine-based activation motifs in hematopoietic cells. Mutations in Btk are involved in impaired B-cell maturation in X-linked agammaglobulinemia, and Btk has been investigated for its role in platelet activation via activation of the effector protein phospholipase Cγ2 downstream of the platelet membrane glycoprotein VI (GPVI). Because of its role in hematopoietic cell signaling, Btk has become a target in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; the covalent Btk inhibitor ibrutinib was recently approved by the US Food and Drug Administration for treatment of these conditions. Antihemostatic events have been reported in some patients taking ibrutinib, although the mechanism of these events remains unknown. We sought to determine the effects of Btk inhibition on platelet function in a series of in vitro studies of platelet activation, spreading, and aggregation. Our results show that irreversible inhibition of Btk with two ibrutinib analogs in vitro decreased human platelet activation, phosphorylation of Btk, P-selectin exposure, spreading on fibrinogen, and aggregation under shear flow conditions. Short-term studies of ibrutinib analogs administered in vivo also showed abrogation of platelet aggregation in vitro, but without measurable effects on plasma clotting times or on bleeding in vivo. Taken together, our results suggest that inhibition of Btk significantly decreased GPVI-mediated platelet activation, spreading, and aggregation in vitro; however, prolonged bleeding was not observed in a model of bleeding.

Original languageEnglish (US)
Pages (from-to)C373-C380
JournalAmerican Journal of Physiology - Cell Physiology
Volume310
Issue number5
DOIs
StatePublished - Mar 1 2016

Fingerprint

Oral Administration
Platelet Activation
Platelet Aggregation
Hemorrhage
Immunoreceptor Tyrosine-Based Activation Motif
Agammaglobulinaemia tyrosine kinase
platelet membrane glycoprotein VI
Mantle-Cell Lymphoma
P-Selectin
Phospholipases
B-Cell Chronic Lymphocytic Leukemia
United States Food and Drug Administration
Fibrinogen
Glycoproteins
B-Lymphocytes
Blood Platelets
Phosphorylation
Mutation
PCI 32765
In Vitro Techniques

Keywords

  • Bruton's tyrosine kinase
  • glycoprotein VI
  • ibrutinib
  • platelets

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. / Rigg, Rachel A.; Aslan, Joseph; Healy, Laura D.; Wallisch, Michael; Thierheimer, Marisa L D; Loren, Cassandra P.; Pang, Jiaqing; Hinds, Monica; Gruber, Andras; McCarty, Owen.

In: American Journal of Physiology - Cell Physiology, Vol. 310, No. 5, 01.03.2016, p. C373-C380.

Research output: Contribution to journalArticle

Rigg, Rachel A. ; Aslan, Joseph ; Healy, Laura D. ; Wallisch, Michael ; Thierheimer, Marisa L D ; Loren, Cassandra P. ; Pang, Jiaqing ; Hinds, Monica ; Gruber, Andras ; McCarty, Owen. / Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. In: American Journal of Physiology - Cell Physiology. 2016 ; Vol. 310, No. 5. pp. C373-C380.
@article{196061d8a15a47dba4e8d71a41a371a0,
title = "Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function",
abstract = "The Tec family kinase Bruton's tyrosine kinase (Btk) plays an important signaling role downstream of immunoreceptor tyrosine-based activation motifs in hematopoietic cells. Mutations in Btk are involved in impaired B-cell maturation in X-linked agammaglobulinemia, and Btk has been investigated for its role in platelet activation via activation of the effector protein phospholipase Cγ2 downstream of the platelet membrane glycoprotein VI (GPVI). Because of its role in hematopoietic cell signaling, Btk has become a target in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; the covalent Btk inhibitor ibrutinib was recently approved by the US Food and Drug Administration for treatment of these conditions. Antihemostatic events have been reported in some patients taking ibrutinib, although the mechanism of these events remains unknown. We sought to determine the effects of Btk inhibition on platelet function in a series of in vitro studies of platelet activation, spreading, and aggregation. Our results show that irreversible inhibition of Btk with two ibrutinib analogs in vitro decreased human platelet activation, phosphorylation of Btk, P-selectin exposure, spreading on fibrinogen, and aggregation under shear flow conditions. Short-term studies of ibrutinib analogs administered in vivo also showed abrogation of platelet aggregation in vitro, but without measurable effects on plasma clotting times or on bleeding in vivo. Taken together, our results suggest that inhibition of Btk significantly decreased GPVI-mediated platelet activation, spreading, and aggregation in vitro; however, prolonged bleeding was not observed in a model of bleeding.",
keywords = "Bruton's tyrosine kinase, glycoprotein VI, ibrutinib, platelets",
author = "Rigg, {Rachel A.} and Joseph Aslan and Healy, {Laura D.} and Michael Wallisch and Thierheimer, {Marisa L D} and Loren, {Cassandra P.} and Jiaqing Pang and Monica Hinds and Andras Gruber and Owen McCarty",
year = "2016",
month = "3",
day = "1",
doi = "10.1152/ajpcell.00325.2015",
language = "English (US)",
volume = "310",
pages = "C373--C380",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function

AU - Rigg, Rachel A.

AU - Aslan, Joseph

AU - Healy, Laura D.

AU - Wallisch, Michael

AU - Thierheimer, Marisa L D

AU - Loren, Cassandra P.

AU - Pang, Jiaqing

AU - Hinds, Monica

AU - Gruber, Andras

AU - McCarty, Owen

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The Tec family kinase Bruton's tyrosine kinase (Btk) plays an important signaling role downstream of immunoreceptor tyrosine-based activation motifs in hematopoietic cells. Mutations in Btk are involved in impaired B-cell maturation in X-linked agammaglobulinemia, and Btk has been investigated for its role in platelet activation via activation of the effector protein phospholipase Cγ2 downstream of the platelet membrane glycoprotein VI (GPVI). Because of its role in hematopoietic cell signaling, Btk has become a target in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; the covalent Btk inhibitor ibrutinib was recently approved by the US Food and Drug Administration for treatment of these conditions. Antihemostatic events have been reported in some patients taking ibrutinib, although the mechanism of these events remains unknown. We sought to determine the effects of Btk inhibition on platelet function in a series of in vitro studies of platelet activation, spreading, and aggregation. Our results show that irreversible inhibition of Btk with two ibrutinib analogs in vitro decreased human platelet activation, phosphorylation of Btk, P-selectin exposure, spreading on fibrinogen, and aggregation under shear flow conditions. Short-term studies of ibrutinib analogs administered in vivo also showed abrogation of platelet aggregation in vitro, but without measurable effects on plasma clotting times or on bleeding in vivo. Taken together, our results suggest that inhibition of Btk significantly decreased GPVI-mediated platelet activation, spreading, and aggregation in vitro; however, prolonged bleeding was not observed in a model of bleeding.

AB - The Tec family kinase Bruton's tyrosine kinase (Btk) plays an important signaling role downstream of immunoreceptor tyrosine-based activation motifs in hematopoietic cells. Mutations in Btk are involved in impaired B-cell maturation in X-linked agammaglobulinemia, and Btk has been investigated for its role in platelet activation via activation of the effector protein phospholipase Cγ2 downstream of the platelet membrane glycoprotein VI (GPVI). Because of its role in hematopoietic cell signaling, Btk has become a target in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; the covalent Btk inhibitor ibrutinib was recently approved by the US Food and Drug Administration for treatment of these conditions. Antihemostatic events have been reported in some patients taking ibrutinib, although the mechanism of these events remains unknown. We sought to determine the effects of Btk inhibition on platelet function in a series of in vitro studies of platelet activation, spreading, and aggregation. Our results show that irreversible inhibition of Btk with two ibrutinib analogs in vitro decreased human platelet activation, phosphorylation of Btk, P-selectin exposure, spreading on fibrinogen, and aggregation under shear flow conditions. Short-term studies of ibrutinib analogs administered in vivo also showed abrogation of platelet aggregation in vitro, but without measurable effects on plasma clotting times or on bleeding in vivo. Taken together, our results suggest that inhibition of Btk significantly decreased GPVI-mediated platelet activation, spreading, and aggregation in vitro; however, prolonged bleeding was not observed in a model of bleeding.

KW - Bruton's tyrosine kinase

KW - glycoprotein VI

KW - ibrutinib

KW - platelets

UR - http://www.scopus.com/inward/record.url?scp=84979986145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979986145&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00325.2015

DO - 10.1152/ajpcell.00325.2015

M3 - Article

C2 - 26659727

AN - SCOPUS:84979986145

VL - 310

SP - C373-C380

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5

ER -